Advertisement
UK markets close in 8 hours 27 minutes
  • FTSE 100

    8,040.38
    0.00 (0.00%)
     
  • FTSE 250

    19,719.37
    0.00 (0.00%)
     
  • AIM

    754.69
    0.00 (0.00%)
     
  • GBP/EUR

    1.1657
    +0.0012 (+0.11%)
     
  • GBP/USD

    1.2499
    +0.0037 (+0.29%)
     
  • Bitcoin GBP

    51,422.16
    -2,008.62 (-3.76%)
     
  • CMC Crypto 200

    1,389.17
    +6.59 (+0.48%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,333.70
    -4.70 (-0.20%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,266.91
    +65.64 (+0.38%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • CAC 40

    8,091.86
    -13.92 (-0.17%)
     

Why Biogen Shares Fell 12.9% in June

Why Biogen Shares Fell 12.9% in June

Biogen (NASDAQ: BIIB) shares slid 12.9% in June, according to data provided by S&P Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis (MS) drug. In a challenge involving rival Mylan, a federal court in West Virginia invalidated Biogen's Tecfidera patent. The decision clears the way for rival Mylan to bring a generic competitor to market.